Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Abstract

Low-dose pulse methotrexate has emerged as one of the most frequently used slow-acting, symptom-modifying antirheumatic drugs in patients with rheumatoid arthritis (RA) because of its favourable risk-benefit profile. Methotrexate is a weak bicarboxylic acid structurally related to folic acid. The most widely used methods for the analysis of methotrexate are… (More)

Topics

Cite this paper

@article{Bannwarth1996ClinicalPO, title={Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.}, author={Bertrand Bannwarth and Fabienne Demotes-Mainard P{\'e}hourcq and Thierry Schaeverbeke and Joachim Dehais}, journal={Clinical pharmacokinetics}, year={1996}, volume={30 3}, pages={194-210} }